Table 5.
Summary of the ongoing studies on GBM immunotherapies testing CAR T cells.
| Trial Name | Phase | Patients (N) | Treatment | Outcomes |
|---|---|---|---|---|
| NCT01109095 | I | 16 | HER2 CMV-specific CAR T cells | DLT |
| NCT01454596 | I/II | 18 | EGFRvIII-directed CAR T cells with cyclophosphamide, fludarabine and aldesleukin | AEs and PFS |
| NCT02208362 | I | 92 | IL13 Rα2-targeted CAR T cells | AEs and DLT |
| NCT02209376 | I | 11 | EGFRvIII-directed CAR T cells | AEs |
| NCT04003649 | I | 60 | IL13 Rα2-targeted CAR T cells with or without nivolumab and ipilimumab | AEs, DLT, feasibility, and OS |
| NCT04077866 | I/II | 40 | B7-H3-targeted CAR T cells with or without temozolomide | OS and PFS |
| NCT04385173 | I | 12 | B7-H3-targeted CAR T cells with temozolomide | AEs, MTD, OS, and PFS |
| NCT04661384 | I | 30 | IL13 Rα2-targeted CAR T cells | AEs and OS |
Abbreviations: AEs = adverse events, CAR T = chimeric antigen receptor T cell, DLT = dose-limiting toxicity, MTD = maximum tolerated dose, OS = overall survival, PFS = progression free survival.